Hepatic encephalopathy (Overt encephalopathy, Covert encephalopathy) Hyperammonemia
Conditions
Interventions
None listed
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Those who are 20 years old or older at the time of obtaining consent 2. Liver disease patients with hyperammonemia (70 g / dl or more) 3. Those who have voluntarily consented to participate in this study
Exclusion criteria
Exclusion criteria: 1.Persons with pulmonary tuberculosis and other tuberculosis 2.Those who are pregnant or breastfeeding 3.Those who have been diagnosed with pseudomembranous enteritis 4.Others who are judged by the principal investigator or coordinator to be inappropriate as research subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in ammonia levels due to rifaximin administration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Changes in hepatic encephalopathy symptoms before and after administration of rifaximin 2.Changes in NP-test test results before and after administration of rifaximin 3.Changes in bacterial translocation markers before and after administration of rifaximin 4.Changes in muscle mass before and after administration of rifaximin 5.Changes in fecal bacterial flora before and after administration of rifaximin 6.Correlation between ammonia value, various blood test values, and NP-test results 7.Correlation between ammonia value and bacterial translocation marker 8.Correlation between ammonia level and endotoxin and preceptin 9.Relationship between ammonia level and fecal bacterial flora | — |
Countries
Japan
Contacts
Public ContactMasato Nakai
Hokkaido University Hospital Gastroenterology and Hepatology
Outcome results
None listed